Optimizing prevention of contrast-induced acute kidney injury in type 2 diabetic patients with at least moderate renal impairment

Chinese Medical Journal

Volumn 125, Issue 19, 2012, Pages 3365-3367

  Shen, Wei feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute kidney injury; Contrast induced; Type 2 diabetic patients

Indexed keywords

ACETYLCYSTEINE; ANISODAMINE; BICARBONATE; CREATININE; CYSTATIN C; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; REACTIVE OXYGEN METABOLITE;

ACUTE KIDNEY FAILURE; ALBUMINURIA; CARDIOVASCULAR PROCEDURE; CLINICAL TRIAL (TOPIC); CONTRAST INDUCED NEPHROPATHY; DRUG MEGADOSE; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY PERFUSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; VASOCONSTRICTION;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; DIABETES MELLITUS, TYPE 2; HUMANS; RISK FACTORS;

EID: 84867425960     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.19.001     Document Type: Editorial

References (33)

1. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care 2005; 28: 2436-2440.
2. Shen WF. Improving long-term outcomes of coronary intervention in patients with diabetes. Chin Med J 2009; 122: 605-607.
3. Dou KF, Xu B, Yang YJ, Chen JL, Qiao SB, Li JJ, et al. Two-year clinical outcome after successful implantation of drug-eluting and bare metal stents in diabetic patients: results from a real-world single center registry. Chin Med J 2009; 122: 612-616.
4. Zhang RY, Ni JW, Zhang JS, Hu J, Yang ZK, Zhang Q, et al. Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. Chin Med J 2006; 119: 1176-1181.
5. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J 2011; 32: 2748-2757.
6. O'Donoghue ML, Vaidya A, Afsal R, Alfredsson J, Boden WE, Braunwald E, et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute syndromes. J Am Coll Cardiol 2012; 60: 106-111.
7. Zhu ZB, Zhang RY, Zhang Q, Zhang JS, Hu J, Yang ZK, et al. Moderate to severe renal insufficiency is a risk factor for sirolimus-eluting stent thrombosis. The RIFT study. Cardiology 2009; 112: 191-199.
8. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro JL, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patietns with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol 2010; 55: 1139-1146.
9. Hung YM, Hung SY, Huang WC, Wang PYP. Preventing radiocontrast-induced nephropathy in chronic kidney disease patients undergoing coronary angiography. World J Cardiol 2012; 26: 157-172.
10. Ding FH, Lu L, Zhang RY, Zhu TQ, Pu LJ, Zhang Q, et al. Impact of elevated serum glycated albumin levels on contrast-induced acute kidney injury in patients with type 2 diabetes mellitus and moderate to severe renal insufficiency undergoing coronary angiography. Int J Cardiol 2012; Epub ahead of print.
11. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51: 1419-1428.
12. Li JH, He NS. Prevention of iodinated contrast-induced nephropathy. Chin Med J 2011;124: 4079-4082.
13. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009;4: 1162-1169.
14. Wang XC, Fu XH, Wang YB, Jia XW, Wu WL, Gu XS, et al. Prediction of contrast-induced nephropathy in patients undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate. Chin Med J 2011; 124: 892-896.
15. Maioli M, Todo A, Leoncini M, Gallopin M, Musilli N, Bellandi F. Persistent renal damage after contrast-induced acute kidney injury: incidence, evolution, risk factors and prognosis. Circulation 2012; 125: 3099-3107.
16. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Risk predictors of contrast-induced nephropathy. Am J Cardiol 2006; 98: 27k-36k.
17. Zhang RY, Zhu ZB, Zhang Q, Yang ZK, Hu J, Lv AK, et al. Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. Int J Cardiol 2009; 136: 72-79.
18. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1391-1399.
19. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-226.
20. Stolker JM, McCullough PA, Rao S, Inzucchi SE, Spertus JA, Maddox TM, et al. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol 2010; 55: 1433-1440.
21. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016.
22. Ziyadeh FN, Cohen MP. Effects of glycated albumin on mesangial cells: evidence for a role in diabetic nephropathy. Mol Cell Biochem 1993; 125: 19-25.
23. Cohen MP, Shea E, Chen S, Shearman CW. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med 2003; 141: 242-249.
24. Weisbourd SD, Palevsky PM. Strategies for the prevention of contrast-induced acute kidney injury. Curr Opin Nephrol Hypertens 2010; 19: 539-549.
25. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010; 122: 2451-2455.
26. Lu L, Peng WH, Wang W, Wang LJ, Chen QJ, Shen WF. Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats. Zhejiang Univ-Sci B 2011; 12: 652-659.
27. Geng W, Fu XH, Gu XS, Wang YB, Wang XC, Li W, et al. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty. Chin Med J 2012; 125: 3368-3372.
28. Wang YB, Fu XH, Gu XS, Wang XC, Zhao YJ, Hao GZ, et al. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome. Chin Med J 2011; 124: 1063-1067.
29. Fu XH, Fan WZ, Gu XS, Wei YY, Jiang YF, Wu WL, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction. Chin Med J 2007; 120: 1226-1231.
30. Dauerman HL. In search of an algorithm to prevent acute kidney injury. JACC Cardiovasc Interv 2009; 2: 1125-1127.
31. Tapuria N, Kumar Y, Habib MM, Abu Amara M, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury - a review. J Surg Res 2008; 150: 304-330.
32. Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, et al. Ischemic preconditioning for prevention of contrast-medium-induced nephropathy: randomized pilot RenPro Trial (renal protection trial). Circulation 2012; 126: 296-303.
33. Bonventre JV. Lim ischemia protects against contrast-induced nephropathy. Circulation 2012; 126: 384-387.